Cellular and Humoral Immunity to SARS-CoV-2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease-Modifying Therapies: A Multi-Ethnic Observational Study.

Ann Neurol · 2022 · PMC9082484 · PMID 35289960

Europe PMC DOI

hedged sentence

0.0640

closest p · 1.3× alpha

0.0640

boldest claim

The sentences

a nonsignificant trendp = 0.064so close (0.05 < p ≤ 0.1)

For OCR‐treated patients with a history of COVID‐19, there was a nonsignificant trend for increased anti‐SARS‐CoV‐2 Ab titers on MBI assay with longer time from the last OCR infusion prior to infection and infection onset ( r = 0.285, p = 0.064).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.